THE GIBSON GROUP, LLC for ENDO PHARMACEUTICALS INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Torts TOR
Issues related to: prescription drug abuse; incentives for tamper-resistant formulations; FDA; Opioids; Medicare Part D rebates; labeling of generic drugs; prescription drug pricing; drug compounding; corporate tax reform; tax treatment of inverted companies; tax issues; patent settlements; patent reform; Mass Torts and Class Action Reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH H GIBSON New | Chief Minority Counsel, House Judiciary Committee 2007-2008; Chief of Staff, Rep. Lamar Smith 2005-2007; Chief Legislative Counsel & Parliamentarian, House Judiciary Committee 2003-2005; Deputy Asst. Attorney General, Office of Leg. Affairs 2002-2003; Counsel for Legislative & Intergovernmental Affairs Anti-Trust Division, DOJ 2001-2002; Chief Antitrust Counsel, House Judiciary Committee 1997-2001; Counsel, House Judiciary Committee 1995-1997 |
Health Issues HCR
Issues related to: prescription drug abuse; incentives for tamper-resistant formulations; FDA; Opioids; Medicare Part D rebates; labeling of generic drugs; prescription drug pricing; drug compounding; corporate tax reform; tax treatment of inverted companies; tax issues; patent settlements; patent reform; Mass Torts and Class Action Reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH H GIBSON New | Chief Minority Counsel, House Judiciary Committee 2007-2008; Chief of Staff, Rep. Lamar Smith 2005-2007; Chief Legislative Counsel & Parliamentarian, House Judiciary Committee 2003-2005; Deputy Asst. Attorney General, Office of Leg. Affairs 2002-2003; Counsel for Legislative & Intergovernmental Affairs Anti-Trust Division, DOJ 2001-2002; Chief Antitrust Counsel, House Judiciary Committee 1997-2001; Counsel, House Judiciary Committee 1995-1997 |
Taxation/Internal Revenue Code TAX
Issues related to: prescription drug abuse; incentives for tamper-resistant formulations; FDA; Opioids; Medicare Part D rebates; labeling of generic drugs; prescription drug pricing; drug compounding; corporate tax reform; tax treatment of inverted companies; tax issues; patent settlements; patent reform; Mass Torts and Class Action Reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH H GIBSON New | Chief Minority Counsel, House Judiciary Committee 2007-2008; Chief of Staff, Rep. Lamar Smith 2005-2007; Chief Legislative Counsel & Parliamentarian, House Judiciary Committee 2003-2005; Deputy Asst. Attorney General, Office of Leg. Affairs 2002-2003; Counsel for Legislative & Intergovernmental Affairs Anti-Trust Division, DOJ 2001-2002; Chief Antitrust Counsel, House Judiciary Committee 1997-2001; Counsel, House Judiciary Committee 1995-1997 |
Copyright/Patent/Trademark CPT
Issues related to: prescription drug abuse; incentives for tamper-resistant formulations; FDA; Opioids; Medicare Part D rebates; labeling of generic drugs; prescription drug pricing; drug compounding; corporate tax reform; tax treatment of inverted companies; tax issues; patent settlements; patent reform; Mass Torts and Class Action Reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH H GIBSON New | Chief Minority Counsel, House Judiciary Committee 2007-2008; Chief of Staff, Rep. Lamar Smith 2005-2007; Chief Legislative Counsel & Parliamentarian, House Judiciary Committee 2003-2005; Deputy Asst. Attorney General, Office of Leg. Affairs 2002-2003; Counsel for Legislative & Intergovernmental Affairs Anti-Trust Division, DOJ 2001-2002; Chief Antitrust Counsel, House Judiciary Committee 1997-2001; Counsel, House Judiciary Committee 1995-1997 |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| ENDO INTERNATIONAL PLC | Ireland | Ireland | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.